stockrow
Monday 9 November 2026
Export VNDA’s income statement to Excel — free account
Vanda Pharmaceuticals Inc.
VNDAVanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024.
- Revenue
- +24.1%
- EPS
- +1.82%
- Free cash flow
- +9.57%
- Total debt
- −16.5%
Quarter to September 2026, against a year earlier
3.82
0.23
+6.41%
Follow VNDA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.29 | 1.71 | 1.89 | 2.41 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.44) | (11.86) | (8.18) | (17.67) | |
P/B ratio |
1.49 | 1.67 | 1.46 | 1.59 | |
Price to Tangible BV |
3.35 | 3.44 | 2.48 | 2.47 | |
EV/Sales |
0.69 | 0.94 | 0.98 | 1.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.14) | (1.42) | (1.68) | (2.38) | |
EV/FCF |
(1.06) | (1.32) | (1.55) | (2.35) | |
Quick Ratio |
1.30 | 1.40 | 1.91 | 2.19 | |
Current Ratio |
1.54 | 1.61 | 2.16 | 2.39 | |
Net Debt/EBITDA |
6.91 | 2.77 | 4.24 | 6.94 | |
Debt/Assets |
0.61% | 0.77% | 0.87% | 0.83% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.47 | 0.42 | 0.41 | 0.38 | |
Operating CF/Net income |
1.26 | 0.50 | 1.03 | 0.21 | |
Capex/Depreciation |
(0.09) | (0.05) | (3.01) | (0.03) | |
Research and Development Expense of Revenue |
39.56% | 73.13% | 54.98% | 50.70% | |
Selling, General and Administrative Expense of Revenue |
85.33% | 142.17% | 132.18% | 110.07% | |
Intangible Assets out of Total Assets |
0.29 | 0.27 | 0.27 | 0.24 | |
Share Based Compensation of Revenue |
3.35% | 4.17% | 4.96% | 3.99% | |
Graham Net Nets |
0.19 | 0.20 | 0.34 | 0.36 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(94.16%) | (75.65%) | (58.61%) | (42.29%) | |
Free Cash Flow Yield |
(50.51%) | (41.51%) | (33.42%) | (21.25%) | |
Revenue per Share |
1.15 | 0.84 | 0.87 | 0.97 | |
Operating CF per Share |
(0.47) | (0.52) | (0.84) | (0.50) | |
Capex per Share |
(0.01) | 0.00 | (0.17) | 0.00 | |
Free Cash Flow per Share |
(0.48) | (0.52) | (1.02) | (0.50) | |
Cash per Share |
2.32 | 2.82 | 3.40 | 4.48 | |
Shareholders Equity per Share |
3.31 | 3.66 | 4.72 | 5.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.31 | 3.66 | 4.72 | 5.55 | |
Free Cash Flow |
(28.75) | (31.26) | (60.44) | (29.52) | |
Working Capital |
83.49 | 100.46 | 157.59 | 202.10 | |
Capital Expenditures |
(0.31) | (0.19) | (10.22) | (0.10) | |
Net Current Asset Value |
56.00 | 72.20 | 140.41 | 185.50 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.20 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
55.43 | 52.34 | 50.74 | 50.84 | |
Average Payables |
54.10 | 63.56 | 52.95 | 53.69 | |
Average Inventory |
1.79 | 1.92 | 1.81 | 1.79 | |
Average Assets |
491.73 | 518.61 | 532.73 | 572.58 | |
Average Common Equity |
332.93 | 353.26 | 396.09 | 432.87 |
Columns are period end dates · fundamentals updated 2 Nov 2026